Artemis Medicare Q1 FY27 PAT jumps 45% YoY on revenue growth
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 1.1 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q1 FY27 standalone revenue rose to Rs 28,201 lakhs (up about 13% from Rs 24,980 YoY). PAT jumped 45% to Rs 3,105 lakhs from Rs 2,142 lakhs. Consolidated PAT was Rs 3,144 lakhs, up about 48%. EBITDA margin expanded to roughly 21.6% from 19.1%. Auditor issued unmodified conclusion. Board also approved Tower IV expansion at Gurugram hospital, adding 200 plus beds at Rs 160 to 180 crore via internal accruals and debt.
Strong earnings signal solid hospital demand. Tower IV expansion adds growth runway, debt-funded Rs 160 to 180 crore capex may pressure margins short term.